Safety and Pharmacokinetics of RTH258 in Subjects With Age-Related Macular Degeneration

Summary

The purpose of this study is to assess the systemic pharmacokinetics (PK) and safety of 2 different doses of brolucizumab (3 milligrams (mg)/50 microliters (μL) and 6 mg/50 μL) when administered at 4-week intervals for a total of 3 intravitreal injections in subjects with neovascular age-related macular degeneration (AMD).

Timeline

Start

2015-08-24

Primary completion

2016-09-06

Completion

2016-09-06

Drugs

Indications